Program
pelabresib
Also written as “Pelabresib” and “CPI-0610”.
In Novartis's pipeline, BET inhibitor
. Its studies are mostly in Primary Myelofibrosis · Hematologic Neoplasms · Lymphoma, Follicular · Lymphoma · Multiple Myeloma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 77 open or running | phase 3since Oct 20, 2020 | Oct 20, 2020 | Mar 9, 2028phase 1 · NCT07340190 |
| Constellation Pharmaceuticals | 40 open or running | phase 2since Jun 5, 2014 | Sep 10, 2013 | none ahead |
- Named in Novartis’s own pipeline as
DAK539 (pelabresib)
, phase 4, as of Nov 16, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 10, 2013First study: phase 1 study in LymphomaNew to Constellation PharmaceuticalsConstellation Pharmaceuticals · NCT01949883 · 64 enrolled
- May 28, 2014Phase 1 study in Multiple MyelomaConstellation Pharmaceuticals · NCT02157636 · 30 enrolled
- Jun 5, 2014Phase 2 study in Primary MyelofibrosisConstellation Pharmaceuticals · NCT02158858 · 336 enrolled · United States, Belgium, Canada and more
- Oct 20, 2020Novartis's first study: phase 3 study in Primary MyelofibrosisNew to NovartisNovartis · NCT04603495 · 430 enrolled · United States, Australia, Austria and more
- May 5, 2022Phase 1 study in Hematologic NeoplasmsConstellation Pharmaceuticals · NCT05391022 · 35 enrolled · United States, Georgia, Spain
- May 2, 2024Phase 3 study in Hematologic NeoplasmsNovartis · NCT06401356 · 50 planned · United States, Belgium, Italy and more
- Jan 6, 20263 phase 1 studiesNovartis · NCT07340190, NCT07340138, NCT07422610
- Jan 15, 2026Phase 3 study in Primary MyelofibrosisNovartis · NCT07357727 · 460 planned · United States, Argentina, Australia and more
- Aug 18, 2026Phase 1 study in Healthy ParticipantsNovartis · NCT07783503 · 30 planned · United Kingdom
- Nov 12, 2026Primary completion moved from 2027-06-02 to 2029-12-31Date moved laterphase 3 · +31 months · NCT06401356
Ahead
- Nov 13, 2026Primary completion: phase 1 study in Healthy ParticipantsNovartis · NCT07783503
- Mar 9, 2028Primary completion: phase 1 study in Advanced MalignanciesNovartis · NCT07340190
- May 17, 2028Primary completion: phase 3 study in Primary MyelofibrosisNovartis · NCT07357727
- Jun 28, 2028Primary completion: phase 1 study in Lymphoma, FollicularNovartis · NCT07422610
TargetBeta
“BET inhibitor”the company's pipeline, read by Claude · source
“The hydrated form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby prevent…”NCIt, read by Claude
“Bromodomain and extra-terminal motif (BET) inhibitor”ChEMBL 37, by rule
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07783503Healthy Participants · United Kingdom | 1 | Recruiting | Novartis | Nov 13, 2026 | 30 |
| NCT07422610Lymphoma, Follicular · France, Italy, Spain and more | 1 | Recruiting | Novartis | Jun 28, 2028 | 24 |
| NCT07357727Primary Myelofibrosis · United States, Argentina, Australia and more | 3 | Recruiting | Novartis | May 17, 2028 | 460 |
| NCT07340190Advanced Malignancies · France, Italy, Spain | 1 | Recruiting | Novartis | Mar 9, 2028 | 24 |
| NCT07340138Primary Myelofibrosis · Japan | 1 | Active, not recruiting | Novartis | Jul 23, 2026 | 3 |
| NCT06401356Hematologic Neoplasms · United States, Belgium, Italy and more | 3 | Recruiting | Novartis | Dec 31, 2029 | 50 |
| NCT05391022Hematologic Neoplasms · United States, Georgia, Spain | 1 | Completed | Constellation Pharmaceuticals | Mar 8, 2023 | 35 |
| NCT04603495Primary Myelofibrosis · United States, Australia, Austria and more | 3 | Active, not recruiting | Novartis | Aug 23, 2023 | 430 |
| NCT02158858Primary Myelofibrosis · United States, Belgium, Canada and more | 2 | Completed | Constellation Pharmaceuticals | Jan 9, 2025 | 336 |
| NCT02157636Multiple Myeloma | 1 | Completed | Constellation Pharmaceuticals | Nov 8, 2016 | 30 |
| NCT01949883Lymphoma | 1 | Completed | Constellation Pharmaceuticals | Dec 20, 2017 | 64 |
How it is read
Names in the registry
- “Pelabresib”, 7 entries
- “pelabresib”, 2 entries
- “CPI-0610”, 2 entries
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 4 studies
- Hematologic Neoplasms, 2 studies
- Lymphoma, Follicular, 1 study
- Lymphoma, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.